BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34482180)

  • 1. How we treat HER2-positive brain metastases.
    Stavrou E; Winer EP; Lin NU
    ESMO Open; 2021 Oct; 6(5):100256. PubMed ID: 34482180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
    Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
    J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.
    Ramakrishna N; Anders CK; Lin NU; Morikawa A; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Franzoi MAB; Kirshner JJ; Krop IE; Patt DA; Perlmutter J; Giordano SH
    J Clin Oncol; 2022 Aug; 40(23):2636-2655. PubMed ID: 35640075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
    Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
    Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
    Leyland-Jones B
    J Clin Oncol; 2009 Nov; 27(31):5278-86. PubMed ID: 19770385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients.
    Galve-Calvo E; Alonso-Babarro A; Martínez-García M; Pi-Figueras M; Villalba G; Alonso S; Contreras J
    Adv Ther; 2023 Aug; 40(8):3304-3331. PubMed ID: 37291377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.
    Ramakrishna N; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Giordano SH; Gonzalez-Angulo AM; Kirshner JJ; Krop I; Levinson J; Modi S; Patt DA; Perez EA; Perlmutter J; Winer EP; Lin NU
    J Clin Oncol; 2014 Jul; 32(19):2100-8. PubMed ID: 24799487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of HER2 status in the treatment for brain metastases arising from breast cancer with stereotactic radiosurgery.
    Tam M; Narayana A; Raza S; Kunnakkat S; Golfinos JG; Parker EC; Novik Y
    Med Oncol; 2014 Feb; 31(2):832. PubMed ID: 24390418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New target therapies for brain metastases from breast cancer.
    Metro G; Fabi A
    Curr Cancer Drug Targets; 2012 Mar; 12(3):210-7. PubMed ID: 22268385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.
    Kuba S; Ishida M; Nakamura Y; Yamanouchi K; Minami S; Taguchi K; Eguchi S; Ohno S
    Jpn J Clin Oncol; 2014 Nov; 44(11):1025-31. PubMed ID: 25156682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases.
    Dong R; Ji J; Liu H; He X
    Crit Rev Oncol Hematol; 2019 Nov; 143():20-26. PubMed ID: 31449983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
    Yomo S; Hayashi M; Cho N
    J Neurooncol; 2013 Apr; 112(2):199-207. PubMed ID: 23296546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.
    Ramakrishna N; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Giordano SH; Kirshner JJ; Krop IE; Levinson J; Modi S; Patt DA; Perlmutter J; Winer EP; Lin NU
    J Clin Oncol; 2018 Sep; 36(27):2804-2807. PubMed ID: 29939840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis.
    Kim JM; Miller JA; Kotecha R; Chao ST; Ahluwalia MS; Peereboom DM; Mohammadi AM; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Abraham J; Moore H; Budd GT; Suh JH
    Neuro Oncol; 2019 May; 21(5):659-668. PubMed ID: 30726965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
    Tomasello G; Bedard PL; de Azambuja E; Lossignol D; Devriendt D; Piccart-Gebhart MJ
    Crit Rev Oncol Hematol; 2010 Aug; 75(2):110-21. PubMed ID: 20004109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
    Freedman RA; Gelman RS; Wefel JS; Melisko ME; Hess KR; Connolly RM; Van Poznak CH; Niravath PA; Puhalla SL; Ibrahim N; Blackwell KL; Moy B; Herold C; Liu MC; Lowe A; Agar NY; Ryabin N; Farooq S; Lawler E; Rimawi MF; Krop IE; Wolff AC; Winer EP; Lin NU
    J Clin Oncol; 2016 Mar; 34(9):945-52. PubMed ID: 26834058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer.
    Chien AJ; Rugo HS
    Breast Cancer Res Treat; 2013 Jan; 137(1):1-12. PubMed ID: 23143215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating Brain Metastases from Breast Cancer: Outcomes after Stereotactic Radiosurgery.
    Wilson TG; Robinson T; MacFarlane C; Spencer T; Herbert C; Wade L; Reed H; Braybrooke JP
    Clin Oncol (R Coll Radiol); 2020 Jun; 32(6):390-396. PubMed ID: 32131980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of stereotactic radiosurgery for brain metastases from breast cancer: who benefits most?
    Cho E; Rubinstein L; Stevenson P; Gooley T; Philips M; Halasz LM; Gensheimer MF; Linden HM; Rockhill JK; Gadi VK
    Breast Cancer Res Treat; 2015 Feb; 149(3):743-9. PubMed ID: 25638395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.